Immunotherapy and Control of Cervical Canal Crypts on HPV – Ways to Reduce Recurrence and Mortality from Cervical Cancer

The results of HPV immunotherapy associated cervical lesions (HSIL) after radio wave conization (534 cases) were analyzed in comparison with the control group (659 women a verified process CIN II-III and CIS, registered at regional cancer center. In 9.55±1.3% cases within 2-3 years HSIL (CIN II-III, CIS), progression disease (dysplasia, situ 2 1st stage) was established group. latter need for introduction cornerstone practices - crypts upper cone cervix on immunotherapy. study group, detected 23.7±1.8% cone. All this prescribed inosine pranobex (isoprinosine). After course treatment, atypia repeated 6, 12 18 months. Relapses patients treated isoprinosine amounted to 0.27 ± 0.5%. difference is statistically significant P less than 0.05. At same time, tracing path from moment screening detection HPV-associated lesions, more half do not receive treatment timely manner. For continuity between specialists, we have introduced signal cards informed consent woman when pathology detected.